Recursion Pharmaceuticals completed its acquisition of Exscientia, exchanging 102,138,419 shares of its Class A Common Stock for Exscientia's shares at a ratio of 0.7729 shares per Exscientia share, making Exscientia a wholly owned subsidiary as of N...